The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort-Reference-Cited by-同舟云学术

The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort

Published:2018-01-17 Issue:5 Volume:25 Page:535-542
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Kozuka R.¹^ORCID,Hai H.¹,Motoyama H.¹,Hagihara A.¹,Fujii H.¹,Uchida‐Kobayashi S.¹,Morikawa H.¹,Enomoto M.¹,Murakami Y.¹,Kawada N.¹,Tamori A.¹^ORCID

Affiliation:

1. Department of HepatologyOsaka City University Graduate School of Medicine Osaka Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12850

Reference35 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

2. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders

3. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

4. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

5. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region;South of Russia: ecology, development;2024-04-07

2. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis;Journal of Gastroenterology;2023-02-02

3. Risk factors for liver‐related and non‐liver‐related mortality following a sustained virological response after direct‐acting antiviral treatment for hepatitis C virus infection in a real‐world cohort;Journal of Viral Hepatitis;2023-01-09

4. The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures;Viruses;2021-12-22

5. Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis;Liver International;2020-06